Chinese Biotechs Raise $743m In Three March IPOs

RemeGen touched down in Shanghai to score a dual listing on top of a 2020 initial public offering in Hong Kong. Meanwhile, domestic HPV vaccine maker Recbio and small molecule-focused Shouyao made their debuts on the Hong Kong and Shanghai markets respectively.

The first biotech IPO on the Beijing Stock Exchange
combined $742.9m in gross proceeds closed out strong March for RemeGen, Recbio and Shouyao • Source: Alamy

Chinese biotechs closed the first quarter with three additional initial public listings in Shanghai and Hong Kong, grossing a combined $742.9m in the last weeks of March.

While the number of new listings reached a new monthly high to date this year, the IPO sizes shrank from the initially planned

More from China

More from Focus On Asia